Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients

Sheriza N. Baksh, Walid F. Gellad, G. Caleb Alexander

Research output: Contribution to journalArticlepeer-review

Abstract

In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi®) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA’s decision, including the product’s two prior failed FDA reviews, the unmet need of women with this disorder, extensive advocacy and politicization surrounding the product’s relevance to women and sexual health, the potential for widespread off-label use, and the product’s tenuous risk/benefit profile. Despite that, attention now shifts to maximizing the safe use of the product, including the optimal means to avoid numerous drug–drug interactions as well as the concomitant use of alcohol, both of which potentiate the risks of dizziness, hypotension, and syncope. Although the FDA has implemented a comprehensive Risk Evaluation and Mitigation Strategies program to maximize the product’s safe use, patients, clinicians, and regulators must exhibit heightened vigilance early in the product’s post-market life.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalDrug Safety
Volume39
Issue number5
DOIs
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients'. Together they form a unique fingerprint.

Cite this